跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TO-195
首页
药物
TO-195
TO-195
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHOD FOR TREATING MUSCULAR DYSTROPHY BY TARGETING LAMA1 GENE
EP 4013874 A1
申请人: MODALIS THERAPEUTICS CORP
优先权: 2019
CN
EP
US
WO
5 件公开
Encapsulated resveratrol (RSV) nanoparticles
US 12599569 B1
申请人: UNIV KING SAUD
优先权: 2024
US
5 件公开
Micro-RNAS of the MIR-15 family modulate cardiomyocyte survival and cardiac repair
US 8513209 B2
申请人: OLSON ERIC
优先权: 2008
US
4 件公开
NOVEL EMOLLIENT COMPOSITION
EP 3360535 A1
申请人: TOTAL MARKETING SERVICES
优先权: 2017
CN
EP
US
3 件公开
Inhibitors of the miR-15 family of micro-RNAs
US 9163235 B2
申请人: MIRAGEN THERAPEUTICS
优先权: 2013
CN
US
3 件公开
Anti-granulysin antibodies and methods of use thereof
CN 105026425 A
申请人: DEV CENTER BIOTECHNOLOGY
优先权: 2013
CN
US
3 件公开
Anti-CD79B antibodies and immunoconjugates and methods of use
US 8545850 B2
申请人: CHEN YVONNE
优先权: 2010
US
3 件公开
Traditional Chinese medicine compound treating sub-health
CN 105232882 A
申请人: ZHAO BINGRONG
优先权: 2015
CN
3 件公开
MICRORNA 195 COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT
EP 4281558 A4
申请人: US GOV VETERANS AFFAIRS
优先权: 2021
CN
EP
2 件公开
LAG-3 PROTEIN MUTANT, AND PREPARATION AND USE THEREOF
US 2024247043 A1
申请人: WUHAN YZY BIOPHARMA CO LTD
优先权: 2021
CN
US
2 件公开
第 1 / 10 页
上一页
下一页
药物
反馈